Drug Trial Radar · NCT06164743
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Jan 11, 2024
Primary completion
May 15, 2024
Study completion May 15, 2024
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification
Conditions
- Inflammation
Interventions
VVN461 Ophthalmic Solution 1.0%Drug
Topical ocular drug
VVN461 Ophthalmic Solution 0.5%Drug
Topical ocular drug
VehicleDrug
Topical ocular drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anterior Chamber Cell (ACC): Categorical CureTime frame: Day 14
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
United Medical Research Institute
Inglewood, California
North Bay Eye Associates
Petaluma, California
Martel Eye Associates
Rancho Cordova, California
ICON Eye Care
Grand Junction, Colorado
Levenson Eye Associates
Jacksonville, Florida
Comprehensive Eye Care, Ltd
Washington, Missouri
Center For Sight - Las Vegas
Las Vegas, Nevada
Cincinnati Eye Institute
Cincinnati, Ohio
Keystone Research
Austin, Texas
Houston Eye Associates
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.